ABBVIE INC's ticker is ABBV and the CUSIP is 00287Y109. A total of 2,966 filers reported holding ABBVIE INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.6%.
About ABBVIE INC
AbbVie Inc. is a pharmaceutical company that specializes in the development and commercialization of innovative medicines. The company was founded in 2013 and is headquartered in North Chicago, Illinois. AbbVie's mission is to improve the lives of people around the world by providing them with access to high-quality, safe, and effective medicines.
AbbVie's portfolio of products includes some of the world's most widely used and recognized medicines. These include Humira, a treatment for rheumatoid arthritis, psoriasis, and other autoimmune diseases, and Imbruvica, a treatment for certain types of cancer. The company also has a strong pipeline of new products in development, including treatments for Alzheimer's disease, Parkinson's disease, and other conditions.
AbbVie is committed to sustainability and social responsibility. The company has set ambitious goals to reduce its environmental impact, including reducing greenhouse gas emissions and water usage. AbbVie also supports a range of charitable organizations and initiatives, including those focused on improving access to healthcare and education.
In conclusion, AbbVie Inc. is a leading pharmaceutical company that is dedicated to improving the lives of people around the world. With a strong portfolio of products and a commitment to sustainability and social responsibility, AbbVie is well-positioned for continued success in the years ahead.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $274,461 | -5.3% | 1,600 | +0.6% | 0.10% | -8.9% |
| Q1 2024 | $289,767 | +15.5% | 1,591 | -1.7% | 0.11% | +15.5% |
| Q4 2023 | $250,861 | +15.5% | 1,619 | +11.1% | 0.10% | +5.4% |
| Q3 2023 | $217,235 | -4.4% | 1,457 | +2.2% | 0.09% | -3.2% |
| Q1 2023 | $227,330 | -13.8% | 1,426 | -12.6% | 0.10% | -17.4% |
| Q4 2022 | $263,691 | +20.4% | 1,632 | +0.2% | 0.12% | +10.6% |
| Q3 2022 | $219,000 | -12.0% | 1,628 | +0.1% | 0.10% | -10.3% |
| Q2 2022 | $249,000 | +6.9% | 1,627 | -5.4% | 0.12% | +10.5% |
| Q1 2022 | $233,000 | 0.0% | 1,720 | 0.0% | 0.10% | 0.0% |
| Q4 2021 | $233,000 | – | 1,720 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 85,000 | $9,574,000 | 9.07% |
| Bruce & Co., Inc. | 368,126 | $41,476,000 | 7.92% |
| swisspartners Advisors Ltd | 81,279 | $9,155,000 | 7.17% |
| INSPIRION WEALTH ADVISORS, LLC | 231,010 | $26,021,000 | 6.41% |
| Iron Triangle Partners LP | 532,523 | $59,983,000 | 6.18% |
| DAVIDSON TRUST CO | 62,315 | $7,019,000 | 5.47% |
| BRANDYWINE TRUST CO | 145,101 | $16,344,000 | 5.17% |
| Raub Brock Capital Management LP | 250,306 | $28,194,000 | 4.86% |
| Orbis Allan Gray Ltd | 6,632,385 | $747,072,000 | 4.72% |
| TSFG, LLC | 103,617 | $11,671,000 | 4.70% |